Phathom Pharmaceuticals (PHAT) announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. Narula most recently served as CFO at Intra-Cellular Therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom clarifies no reduction in lead shareholder’s ownership amid 13D filing
- Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Phathom Pharmaceuticals Reports Strong Q2 Growth
- Phathom Pharmaceuticals: Strong Buy Rating Driven by Robust Revenue Performance and Growth Potential
- Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)